17基因基因组前列腺评分测试预测不良中危前列腺癌结局
本研究基于两项根治性前列腺切除术后队列(CPDR与KPNC),评估基因组前列腺评分(GPS)与不良中危(UFI)前列腺癌患者生化复发(BCR)、远处转移(DM)和前列腺癌特异性死亡(PCD)的关联。结果显示GPS以≤40 vs >40二分值时显著预测UFI患者BCR,GPS>40者结局类似高危,GPS≤40者类似有利中危。
要点
- GPS二分值≤40 vs >40可预测UFI患者BCR(CPDR HR 6.0)。
- GPS对BCR、DM和PCD均为强预测因子(KPNC多变量分析)。
- GPS>40的UFI患者预后差,或可从额外治疗中获益。
核心结论
- GPS是中危前列腺癌BCR、DM和PCD的强独立预测因子。
- UFI患者中GPS>40者预后差,可能受益于额外治疗选择。
研究设计与样本
- 分析两项研究(CPDR和KPNC)中接受根治性前列腺切除术的男性GPS结果。
- 纳入299例中危前列腺癌患者,其中175例为UFI风险(KPNC 103例;CPDR 72例)。
主要发现
- GPS>40的UFI患者结局与高危疾病一致,而GPS≤40的UFI患者结局与FI风险患者相似(CPDR/KPNC)。
临床怎么用
- GPS检测可用于UFI风险前列腺癌患者的风险分层,帮助识别可能受益于额外治疗的高危亚群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the association of the Genomic Prostate Score (GPS) assay result with biochemical recurrence (BCR), distant metastases (DM), and prostate-specific death (PCD) in unfavorable intermediate (UFI) risk prostate cancer patients. The GPS assay is used to help guide management decisions for newly diagnosed low and favorable intermediate (FI) risk disease. METHODS: GPS results from 2 studies (Center for Prostate Disease Research [CPDR]; Kaiser Permanente Northern California [KPNC]) in men treated with radical prostatectomy were analyzed to determine associations of the GPS result with BCR, DM, and PCD in UFI risk disease. Analyses included 299 intermediate risk prostate patients, 175 of whom had UFI risk disease (KPNC = 103; CPDR = 72). RESULTS: The GPS result as a dichotomous value (≤40 vs >40) was a significant predictor of BCR in UFI patients in multivariate analyses (hazard ratio [HR] 6.0; 95% confidence interval [CI] 2.0-22.4; P = .0035; CPDR). The GPS result was a strong predictor of all 3 endpoints in multivariate analyses (BCR HR 7.1; 95% CI 5.7-8.8; P < .0001; DM HR 5.4; 95% CI 3.8-7.8; P < .0001; PCD HR 3.4; 95% CI 1.5-8.9; P = .006; KPNC). UFI patients with GPS >40 had outcomes consistent with high-risk disease, whereas UFI patients with GPS ≤40 had outcomes similar to FI risk patients (CPDR/KPNC). CONCLUSIONS: The GPS result was a strong independent predictor of BCR, DM, and PCD in intermediate risk prostate cancer. UFI patients with GPS >40 have a poor prognosis and may benefit from additional therapeutic options.
引用
- Cullen J, Kuo HC, Shan J, et al. The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer. Urology. 2020. PMID: 32525077. doi:10.1016/j.urology.2020.05.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。